Category: health – Page 361
We are learning more about fungal infection and neurological diseases. Recently we learned of gingival diseases and Alzheimer’s. My wonder is how plants such as Moringa in one’s diet, that have antifungal properties, can help.
Fungal infections are emerging as a major medical challenge, and a team led by researchers at Baylor College of Medicine has developed a mouse model to study the short-term consequences of fungal infection in the brain.
The researchers report in the journal Nature Communications the unexpected finding that the common yeast Candida albicans, a type of fungus, can cross the blood-brain barrier and trigger an inflammatory response that results in the formation of granuloma-type structures and temporary mild memory impairments in mice. Interestingly, the granulomas share features with plaques found in Alzheimer’s disease, supporting future studies on the long-term neurological consequences of sustained C. albicans infection.
“An increasing number of clinical observations by us and other groups indicates that fungi are becoming a more common cause of upper airway allergic diseases such as asthma, as well as other conditions such as sepsis, a potentially life-threatening disease caused by the body’s response to an infection,” said corresponding author Dr. David B. Corry, professor of medicine-immunology, allergy and rheumatology and Fulbright Endowed Chair in Pathology at Baylor College of Medicine.
Read more
It won’t be simple. As with the advent of the car, many serious implications will be emergent, and the harshest effects borne by communities with the least powerful voices. We need to move our gaze from individuals to systems to communities, and back again. We must bring together diverse expertise, including workers and citizens, to develop a framework that health systems can use to anticipate and address issues. This framework needs an explicit mandate to consider and anticipate the social consequences of AI — and to keep watch over its effects. That is the best way to ensure that health technologies meet the needs of all, and not just those in Silicon Valley.
Health authorities are overlooking risks to systems and society in their evaluations of new digital technologies, says Melanie Smallman.
Read more
The Future of Mental Health
Posted in health, neuroscience
The biggest source of variability in the microbiome is the person-to-person variability. It’s a problem if you’re looking for causality. That’s a red flag word for us – causality – meaning something about the bacterial community causes some disease. You actually don’t know whether it’s the bacteria or whether the bacteria are a sign of something that happened before. It’s very much individualized, so everybody’s history matters.
We are all teeming with bacteria that help us digest food or fight disease, but two people might play host to a very different array of bacteria due to diet, where they live, hobbies or even medical histories.
As a result, scientists have struggled to understand which bacteria are linked to disease and which protect against it. Studies comparing people’s bacterial companions – known as the microbiome – to explore what that variation means might disagree because they analyzed different groups or didn’t sample enough people.
Statistics Professor Susan Holmes thinks one way of teasing out which differences are relevant to disease and which are just differences between people could come down to statistics and repeating studies.
Read more
By tapping nutrients from bedrock, red alder trees play a key role in healthy forest ecosystems, according to a new study.
The study published today in the journal Proceedings of the National Academy of Sciences.
Researchers from Oregon State University and the U.S. Geological Survey determined red alder, through its symbiotic relationship with nitrogen-fixing bacteria, taps nutrients that are locked in bedrock, such as calcium and phosphorus. This process accelerates rock dissolution, releasing more mineral nutrients that allow plants and trees to grow.
Read more
The phenomenon of ‘microdosing’, that is, regular ingestion of very small quantities of psychedelic substances, has seen a rapid explosion of popularity in recent years. Individuals who microdose report minimal acute effects from these substances yet claim a range of long-term general health and wellbeing benefits. There have been no published empirical studies of microdosing and the current legal and bureaucratic climate makes direct empirical investigation of the effects of psychedelics difficult. In Study One we conducted a systematic, observational investigation of individuals who microdose. We tracked the experiences of 98 microdosing participants, who provided daily ratings of psychological functioning over a six week period. 63 of these additionally completed a battery of psychometric measures tapping mood, attention, wellbeing, mystical experiences, personality, creativity, and sense of agency, at baseline and at completion of the study. Analyses of daily ratings revealed a general increase in reported psychological functioning across all measures on dosing days but limited evidence of residual effects on following days. Analyses of pre and post study measures revealed reductions in reported levels of depression and stress; lower levels of distractibility; increased absorption; and increased neuroticism. To better understand these findings, in Study Two we investigated pre-existing beliefs and expectations about the effects of microdosing in a sample of 263 naïve and experienced microdosers, so as to gauge expectancy bias. All participants believed that microdosing would have large and wide-ranging benefits in contrast to the limited outcomes reported by actual microdosers. Notably, the effects believed most likely to change were unrelated to the observed pattern of reported outcomes. The current results suggest that dose controlled empirical research on the impacts of microdosing on mental health and attentional capabilities are needed.
Citation: Polito V, Stevenson RJ (2019) A systematic study of microdosing psychedelics. PLoS ONE 14: e0211023. https://doi.org/10.1371/journal.pone.
Editor: Danilo Arnone, King’s College London, UNITED KINGDOM
Read more